We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

77 hedge funds and large institutions have $116M invested in Synergy Pharmaceuticals, Inc Common Stock in 2013 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 18 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 18

84% more call options, than puts

Call options by funds: $381K | Put options by funds: $207K

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

9% more capital invested

Capital invested by funds: $106M → $116M (+$9.5M)

7% more funds holding

Funds holding: 7277 (+5)

Holders
77
Holders Change
+5
Holders Change %
+6.94%
% of All Funds
2.5%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
35
Reduced
18
Closed
6
Calls
$381K
Puts
$207K
Net Calls
+$174K
Net Calls Change
+$441K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$18.7M +$612K +136,574 +3%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$15.8M -$543K -121,072 -3%
BFA
3
BlackRock Fund Advisors
California
$14.9M +$1.87M +417,641 +14%
BBA
4
Baker Bros. Advisors
New York
$11.9M
State Street
5
State Street
Massachusetts
$5.65M +$1.32M +293,388 +31%
Northern Trust
6
Northern Trust
Illinois
$5M +$1.23M +273,298 +33%
BIT
7
BlackRock Institutional Trust
California
$4.91M +$318K +70,971 +7%
WSA
8
Wall Street Associates
California
$4.31M -$70.5K -15,717 -2%
Morgan Stanley
9
Morgan Stanley
New York
$4.01M -$129K -28,758 -3%
UBS AM
10
UBS AM
Illinois
$2.85M +$2.84M +633,446 New
Deutsche Bank
11
Deutsche Bank
Germany
$2.27M +$220K +49,087 +11%
Cambridge Investment Research Advisors
12
Cambridge Investment Research Advisors
Iowa
$2.05M +$351K +78,336 +21%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$1.85M +$244K +54,425 +15%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.84M +$179K +39,828 +11%
TCIM
15
TIAA CREF Investment Management
New York
$1.74M -$134K -29,834 -7%
B
16
Bailard
California
$1.56M
Nomura Holdings
17
Nomura Holdings
Japan
$1.28M +$1.27M +283,413 New
HighTower Advisors
18
HighTower Advisors
Illinois
$1.11M +$395K +88,131 +56%
BIM
19
BlackRock Investment Management
Delaware
$1.04M +$78.9K +17,598 +8%
TSW
20
Thompson Siegel & Walmsley
Virginia
$848K +$153K +34,019 +22%
Charles Schwab
21
Charles Schwab
California
$742K +$4 +1 +0%
TMC
22
Trellus Management Company
Florida
$712K
APU
23
Alpine Partners USVI
U.S. Virgin Islands
$697K +$693K +154,635 New
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$659K +$17.3K +3,853 +3%
TA
25
Teachers Advisors
New York
$511K +$25.7K +5,735 +5%

SGYP Hedge Fund Activity: Q3 2013 in Review

77 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2013, worth a combined $116M — up 9% from $106M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new SGYP positions and 6 closed out — a net gain of 5 holders — while 35 added to existing stakes and 18 trimmed.

The largest buyer was UBS AM, opening a new position worth an estimated $2.84M. The largest seller was Bridger Management, exiting entirely with an estimated $4.6M sold.

  • 77 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2013, up from 72 in Q2 2013.
  • Funds reported $116M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2013, up 9% quarter-over-quarter.
  • 11 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2013 and 6 closed out, a net change of +5 holders.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2013 was UBS AM, an estimated $2.84M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2013 was Bridger Management, an estimated $4.6M sold.

Based on aggregated 13F filings for Q3 2013.